Form 4: Arcus Biosciences President Jaen Juan C. Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Arcus Biosciences' President, Jaen Juan C., reports a transaction involving common stock due to the net settlement of RSUs for tax obligations.
Summary
- On June 15, 2024, Jaen Juan C., President of Arcus Biosciences, Inc., reported a transaction involving the company's common stock.
- The transaction involved the net settlement of 6,969 shares to cover tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
- The shares were disposed of at a price of $16.97 per share.
- Following the transaction, Jaen Juan C. directly owns 334,506 shares of common stock and indirectly owns 1,188,233 shares through a trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares being disposed of by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 06/15/2024 | Date of the transaction involving the net settlement of RSUs. |
| 06/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.